Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agilent Technologies (NYSE:A) Inc after Monday's close announced fourth quarter 2023 financial results that exceeded expectations on both the top and bottom lines.  The analytical and clinical laboratory technologies provider's adjusted earnings per share (EPS) for the period declined 10% year over year to $1.38, while its revenue fell 9% to $1.69 billion.

Agilent Technologies stock higher as 4Q results beat estimates

Agilent Technologies Inc.'s A stock initially rose 3.5% in extended trading Monday after the company reported quarterly results that topped analyst revenue and earnings estimates. Agilent posted fiscal fourth-quarter net income of $475 million, or $1.62 a share, compared with net income of $368 million, or $1.23 a share, in the year-ago quarter.

Agilent's stock is rising on earnings, revenue beats

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.69 billion for the fourth quarter ended Oct. 31, 2023, a decline of 8.7% reported and 9.7% core(1) compared to the fourth quarter of 2022. Fourth-quarter GAAP net income was $475 million, or $1.62 per share. This compares with $368 million, or $1.23 per share, in the fourth quarter of fiscal year 2022. Non-GAAP(2) net income was $404 million, or $1.38 per share during the quarter, compared wit.

Agilent Reports Fourth-Quarter Fiscal Year 2023 Financial Results

Exact Sciences

Soleno Therapeutics

In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. These biotech companies are not only doing the job, but also have potential for future growth.

3 Biotech Stocks With Big-Time Breakthrough Potential

Agilent Technologies (NYSE:A) has been downgraded from ‘Buy' to ‘Neutral' by UBS analysts who believe that the life sciences and diagnostics company's overexposure to regional headwinds in China, instrument demand normalization and softening cyclical spending could pressure forecasts. They highlighted that Agilent makes 20% of its sales in China but a lack of government stimulus, anti-corruption efforts, reshoring, and limited funding availability have pressured biopharma demand in the country.

Agilent Technologies' overexposure to China headwinds prompts analyst downgrade

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 6th Annual Evercore ISI HealthCONx conference on Wednesday, Nov. 29, at 10:50 a.m. ET. A live webcast and audio archive of the virtual session will be available in the News and Events section of Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (N.

Agilent to Present at the Evercore ISI HealthCONx Conference

Agilent Technologies has a fantastic track record of strong EPS growth and outperforming capital gains. More recently, the company has faced challenges with declining stock prices and negative headlines, including workforce cuts and declining revenue. Despite these challenges, Agilent remains confident in its long-term growth prospects, particularly in the pharmaceutical and life sciences markets.

Agilent Technologies: Looking Undervalued Heading Into Earnings

Agilent's (A) results for the fiscal fourth quarter are expected to reflect strength across the ACG amid weakness in the LSAG segment.

What to Note Ahead of Agilent Technologies' (A) Q4 Earnings

Agilent (A) receives FDA approval for its PD-L1 IHC 22C3 diagnostic tool, benefiting PD1/PDL1 cancer patients.

Agilent (A) Boosts DGG Offerings With PD-L1 IHC 22C3 Approval

Albemarle

Carrier Global

Celsius Holdings

Campbell Soup

Edwards Lifesciences

Home Depot

Keurig Dr Pepper Inc

Kimberly-Clark

ResMed

Stocks that are under-earning and trading below historical averages may benefit if inflation continues to cool, according to Wolfe Research.

These 10 Stocks Are Laggards. They May Be Too Cheap To Ignore.

In the closing of the recent trading day, Agilent Technologies (A) stood at $113.60, denoting a +1.78% change from the preceding trading day.

Agilent Technologies (A) Beats Stock Market Upswing: What Investors Need to Know

Agilent Technologies Inc. A, +1.78% late Wednesday said it has increased its dividend 5% to 23.6 cents a share. The dividend will be paid on Jan. 24 to shareholders of record as of the close of business on Jan. 2, the company said.

Agilent raises dividend by 5%

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 24, 2024, to all shareholders of record as of the close of business on Jan. 2, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agi.

Agilent Increases Cash Dividend to 23.6 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic that can identify gastric or GEJ adenocarcinoma patients sui.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck

NIKE

Automatic Data Processing

American Equity Investment Life

Assurant

Atmos Energy

Becton, Dickinson and Co.

Cencora Inc

CubeSmart

Emerson Electric

Evergy Inc

Huntington Ingalls Industries

Hormel Foods

Lancaster Colony

Matthews International

McCormick

Motorola Solutions

Nelnet

Royal Gold

Roper Technologies

Snap-on

Spire

York Water

Investors were rewarded with 10%+ dividend increases from Snap-on Tools and ADP in the first half of November. Other companies that rewarded investors in the first two weeks of the month were Emerson, which extended its dividend growth streak to 67 years, and utilities Atmos and Evergy. The second half of the month will bring dividend increases from Nike, Merck, Hormel and Agilent, among others.

Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In Second Half Of November

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader Award. A professor in the Environmental and Molecular Toxicology Department at Oregon State University's College of Agricultural Sciences, Dr. Field focuses her research on the quantitative analysis of organic micropollutants and their transformation products in natura.

Agilent Announces Thought Leader Award to Professor Jennifer Field

Agilent Technologies (A) reachead $109.39 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.

Agilent Technologies (A) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Agilent Technologies (A) stood at $104.31, denoting a +0.88% change from the preceding trading day.

Agilent Technologies (A) Increases Despite Market Slip: Here's What You Need to Know

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the fourth quarter of fiscal year 2023 after the stock market closes on Monday, Nov. 20. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call will also be available on the website for 90 days. About.

Agilent to Announce Fourth-Quarter Fiscal Year 2023 Financial Results Nov. 20

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company's near and long-term targets for reaching net-zero greenhouse gas emissions have been approved by the Science Based Targets initiative (SBTi). The targets support the ambitious goal to limit planetary warming to 1.5°C above pre-industrial levels. “Companies have an important role to play in driving the transition to a green economy,” said Agilent President and CEO Mike McMullen. “Having measura.

Agilent's Net-Zero Emissions Targets Approved by the Science Based Targets Initiative

Agilent (A) collaborates with Sarawak Infectious Disease Centre to provide the latter with its 6475 triple quadrupole LC/MS system, enabling rapid outbreak response for neglected tropical diseases.

Agilent (A) Bolsters NTD Research With SIDC Partnership

Analog Devices

Autodesk

Amazon

American Express

Boeing

Bank of America

Biogen

Bank of New York Mellon

Blackrock Inc

Bristol-Myers

Colgate-Palmolive

Clorox

Comcast

Compass Minerals

Salesforce

Corteva Inc

Disney

Ecolab

Equifax

Estee Lauder

Etsy

Fortinet

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The October 2023 Heat Map

News for Agilent Technologies Stock (A)